This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Consider ACMR stock: analysts' thoughts
Stocks · News reference
Harmony Biosciences Hldgs Affirms FY2026 Sales Guidance of $1.000B-$1.040B vs $1.020B Est
Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms FY2026 sales outlook from $1.000 billion-$1.040 billion to $1.000 billion-$1.040 billion vs $1.020 billion estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wolfe Research Initiates Coverage On Harmony Biosciences Hldgs with Outperform Rating, Announces Price Target of $60
Wolfe Research analyst Rudy Li initiates coverage on Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform rating and announces Price Target of $60.
Truist Securities Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $34
Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Hold and raises the price target from $29 to $34.
Harmony Biosciences Says New Data Supports Neurology Pipeline
Harmony Biosciences stock jumped after record Q2 revenue, an earnings beat, strong WAKIX sales and updated analyst price targets.